

Sean E Lawler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3177321/publications.pdf>

Version: 2024-02-01

85
papers

5,432
citations

126907

33
h-index

98798

67
g-index

88
all docs

88
docs citations

88
times ranked

10141
citing authors

#	ARTICLE	IF	CITATIONS
1	NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 1460-1473.	7.0	26
2	Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. , 2022, 10, e003368.		9
3	Metabolic Reprogramming of Glioblastoma Cells during HCMV Infection Induces Secretome-Mediated Paracrine Effects in the Microenvironment. <i>Viruses</i> , 2022, 14, 103.	3.3	7
4	Drug Resistance in Glioma Cells Induced by a Mesenchymal-“Amoeboid Migratory Switch. <i>Biomedicines</i> , 2022, 10, 9.	3.2	10
5	A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood-“Brain Barrier Permeability and Targets Glioblastoma. <i>Cancers</i> , 2022, 14, 2207.	3.7	7
6	Inflammasome activation: from molecular mechanisms to autoinflammation. <i>Clinical and Translational Immunology</i> , 2022, 11, .	3.8	12
7	STING activation promotes robust immune response and NK cell-“mediated tumor regression in glioblastoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	44
8	<i>Plasmodium falciparum</i> erythrocyte membrane protein 1 variants induce cell swelling and disrupt the blood-“brain barrier in cerebral malaria. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	43
9	Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican. <i>Advanced Therapeutics</i> , 2021, 4, 2000244.	3.2	11
10	Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. <i>Science Advances</i> , 2021, 7, .	10.3	38
11	Cytomegalovirus infection of glioblastoma cells leads to NF-“B dependent upregulation of the c-MET oncogenic tyrosine kinase. <i>Cancer Letters</i> , 2021, 513, 26-35.	7.2	2
12	The Multifaceted Role of Macrophages in Oncolytic Virotherapy. <i>Viruses</i> , 2021, 13, 1570.	3.3	11
13	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi177-vi177.	1.2	0
14	EXTH-81. STING ACTIVATION PROMOTES ROBUST IMMUNE RESPONSE AND TUMOR REGRESSION IN GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2021, 23, vi182-vi182.	1.2	0
15	DDRE-35. PRE-CLINICAL ASSESSMENT OF PPRX-1701, A NANOPARTICLE FORMULATION OF 6-BROMO-ACETOXIME, FOR THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi82-vi82.	1.2	0
16	DDRE-47. ASSESSMENT OF BRAIN PENETRANCE, BIODISTRIBUTION, AND EFFICACY OF PLATINUM (IV)-CONJUGATED FLUORINATED MACROCYCLIC CELL-PENETRATING PEPTIDES IN A MURINE GLIOBLASTOMA MODEL. <i>Neuro-Oncology</i> , 2021, 23, vi84-vi85.	1.2	0
17	CSIG-19. DISRUPTION OF DNA DAMAGE RESPONSE MODULATES THE EFFICACY OF LOCAL IMMUNOTHERAPIES IN EXPERIMENTAL GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi37-vi37.	1.2	0
18	GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. <i>Cancers</i> , 2021, 13, 5939.	3.7	5

#	ARTICLE	IF	CITATIONS
19	CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2021, 23, vi52-vi52.	1.2	1
20	Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 754443.	3.5	4
21	Collective invasion of glioma cells through OCT1 signalling and interaction with reactive astrocytes after surgery. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2020, 375, 20190390.	4.0	10
22	Cytomegalovirus Encephalopathy during Brain Tumor Irradiation. <i>Clinical Cancer Research</i> , 2020, 26, 3077-3078.	7.0	1
23	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
24	Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model. <i>Cancer Imaging</i> , 2020, 20, 35.	2.8	11
25	A Platinum(IV) Prodrug Perfluoroaryl Macrocyclic Peptide Conjugate Enhances Platinum Uptake in the Brain. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6741-6747.	6.4	20
26	Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification, and validation of miR-1300. <i>Oncogene</i> , 2020, 39, 5292-5306.	5.9	5
27	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	9.7	43
28	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1931.	4.1	20
29	Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment. <i>Frontiers in Physiology</i> , 2020, 11, 151.	2.8	33
30	468...Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma. , 2020, , .		0
31	Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy. <i>Pharmaceutical Patent Analyst</i> , 2019, 8, 87-90.	1.1	20
32	Characterisation of the anti-migratory activity of the 6-bromoindirubin-3-oxime (BIO) derivative VTIND42 in patient-derived GBM subpopulations. <i>Neuro-Oncology</i> , 2019, 21, iv6-iv7.	1.2	0
33	The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. <i>Nature Communications</i> , 2019, 10, 442.	12.8	86
34	Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration. <i>Cancers</i> , 2019, 11, 466.	3.7	24
35	Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy. <i>Trends in Molecular Medicine</i> , 2019, 25, 412-427.	6.7	92
36	Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data. <i>Analytical Chemistry</i> , 2019, 91, 6206-6216.	6.5	45

#	ARTICLE	IF	CITATIONS
37	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1588555.	12.2	86
38	CSIG-19. CYTOMEGALOVIRUS INFECTION LEADS TO NF- κ B DEPENDENT UPREGULATION OF c-MET AND MGMT IN GLIOBLASTOMA AND RESISTANCE TO TEMOZOLOMIDE IN VIVO. <i>Neuro-Oncology</i> , 2019, 21, vi48-vi48.	1.2	0
39	DDIS-36. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi71-vi71.	1.2	1
40	IMMU-46. EXAMINATION OF THE EFFECTS OF DEXAMETHASONE ON THE EFFICACY OF IMMUNOTHERAPY IN GLIOMA USING GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi129-vi129.	1.2	0
41	CBMT-05. GENETIC AND EPIGENETIC MECHANISMS REGULATING SCD INHIBITOR SENSITIVITY IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi33-vi33.	1.2	0
42	TMIC-23. A SEQUENTIAL IMAGING STRATEGY TO STUDY ONCOLYTIC VIRUS INFILTRATION, REPLICATION AND TUMOR MICROENVIRONMENTAL PERTURBATIONS, EX VIVO. <i>Neuro-Oncology</i> , 2019, 21, vi252-vi252.	1.2	0
43	A computationally inspired in-vivo approach identifies a link between amygdalar transcriptional heterogeneity, socialization and anxiety. <i>Translational Psychiatry</i> , 2019, 9, 336.	4.8	22
44	The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health. <i>Free Radical Biology and Medicine</i> , 2019, 130, 215-233.	2.9	59
45	Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. <i>Journal of Clinical Investigation</i> , 2019, 129, 1671-1683.	8.2	52
46	Characterization of glioblastoma in an orthotopic mouse model with magnetic resonance elastography. <i>NMR in Biomedicine</i> , 2018, 31, e3840.	2.8	25
47	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	10.3	416
48	Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. <i>Cancer Letters</i> , 2018, 416, 138-148.	7.2	29
49	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 225-235.	1.2	61
50	Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells. <i>Neuro-Oncology</i> , 2018, 20, 203-214.	1.2	22
51	Novel non-nucleotidic STING agonists for cancer immunotherapy. <i>Future Medicinal Chemistry</i> , 2018, 10, 2767-2769.	2.3	7
52	Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics. <i>Nature Protocols</i> , 2018, 13, 2827-2843.	12.0	185
53	Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. <i>Nature Communications</i> , 2017, 8, 15623.	12.8	224
54	Perfluoroarene-Based Peptide Macrocyces to Enhance Penetration Across the Blood-Brain Barrier. <i>Journal of the American Chemical Society</i> , 2017, 139, 15628-15631.	13.7	60

#	ARTICLE	IF	CITATIONS
55	Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. <i>Neuro-Oncology</i> , 2017, 19, 463-465.	1.2	2
56	Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. <i>Scientific Reports</i> , 2017, 7, 2602.	3.3	40
57	Oncolytic Viruses in Cancer Treatment. <i>JAMA Oncology</i> , 2017, 3, 841.	7.1	426
58	DDIS-19. NOVEL PEPTIDE HOMING TO GLIOMA-SPECIFIC ISOFORM OF BREVICAN SELECTIVELY TARGETS MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2017, 19, vi62-vi63.	1.2	1
59	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS A BIOMARKER FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi114-vi114.	1.2	0
60	BKM-120 (Buparlisib): A Phosphatidylinositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. <i>Scientific Reports</i> , 2016, 6, 20189.	3.3	38
61	Design of a Microfluidic Chip for Magnetic-Activated Sorting of One-Bead-One-Compound Libraries. <i>ACS Combinatorial Science</i> , 2016, 18, 271-278.	3.8	8
62	Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses. <i>ILAR Journal</i> , 2016, 57, 63-72.	1.8	10
63	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. <i>Molecular Oncology</i> , 2016, 10, 1296-1304.	4.6	19
64	ATPS-08DISCOVERY OF NOVEL GLIOMA-TARGETING PEPTIDES USING A HIGH-THROUGHPUT MICROFLUIDIC MAGNETIC-ACTIVATED SORTER. <i>Neuro-Oncology</i> , 2015, 17, v19.4-v19.	1.2	0
65	Strategies of Eradicating Glioma Cells: A Multi-Scale Mathematical Model with MiR-451-AMPK-mTOR Control. <i>PLoS ONE</i> , 2015, 10, e0114370.	2.5	42
66	Glucose-Based Regulation of miR-451/AMPK Signaling Depends on the OCT1 Transcription Factor. <i>Cell Reports</i> , 2015, 11, 902-909.	6.4	50
67	IMPS-21EFFECT OF rQNestin 34.5 ONCOLYTIC HERPES VIRUS ON IMMUNE CHECKPOINT GENE EXPRESSION IN GLIOBLASTOMA CELLS AND EVALUATION OF THERAPEUTIC EFFICACY. <i>Neuro-Oncology</i> , 2015, 17, v117.4-v118.	1.2	0
68	Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. <i>British Journal of Cancer</i> , 2015, 112, 693-703.	6.4	30
69	Cytomegalovirus and glioblastoma; controversies and opportunities. <i>Journal of Neuro-Oncology</i> , 2015, 123, 465-471.	2.9	41
70	In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. <i>Gene Therapy</i> , 2015, 22, 947-959.	4.5	12
71	Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 2812-2814.	1.6	36
72	Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. <i>Molecular Oncology</i> , 2015, 9, 704-714.	4.6	56

#	ARTICLE	IF	CITATIONS
73	Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4269-4280.	8.2	57
74	Targeting Glioblastoma Invasion with GSK-3 inhibitors: Rapid Effects on the EMT Marker Vimentin. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, S1-S2.	0.5	0
75	USP11 regulates PML stability to control Notch-induced malignancy in brain tumours. <i>Nature Communications</i> , 2014, 5, 3214.	12.8	83
76	MicroRNAs in cancer: biomarkers, functions and therapy. <i>Trends in Molecular Medicine</i> , 2014, 20, 460-469.	6.7	1,732
77	Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1. <i>Cancer Research</i> , 2014, 74, 738-750.	0.9	197
78	Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation. <i>Oncoscience</i> , 2014, 2, 252-262.	2.2	12
79	N-Acetylaspartate (NAA) and N-Acetylaspartylglutamate (NAAG) Promote Growth and Inhibit Differentiation of Glioma Stem-like Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 26188-26200.	3.4	44
80	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. <i>Nature Medicine</i> , 2012, 18, 1827-1834.	30.7	164
81	Indirubins Decrease Glioma Invasion by Blocking Migratory Phenotypes in Both the Tumor and Stromal Endothelial Cell Compartments. <i>Cancer Research</i> , 2011, 71, 5374-5380.	0.9	65
82	MicroRNAs and glioblastoma; the stem cell connection. <i>Cell Death and Differentiation</i> , 2010, 17, 221-228.	11.2	99
83	Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. <i>Neuro-Oncology</i> , 2008, 10, 690-699.	1.2	105
84	Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses. <i>Cancer Research</i> , 2007, 67, 9398-9406.	0.9	151
85	Self-assembled ruthenium and osmium nanosystems display potent anticancer profile by interfering with metabolic activity. <i>Inorganic Chemistry Frontiers</i> , 0, , .	6.0	1